| Title: |
Email string – Weight gain and SERM (07/20/2001) |
|
Document Date:
|
20010720
|
|
Document Type:
|
email
|
|
Case Number:
|
Seroquel Products Litigation, 06-MD-01769, US District Court, Middle District of Florida
|
|
Bates Number:
|
azser6992706
|
|
Exhibit Number:
|
Dev 25
|
|
Date Added UCSF:
|
20100218
|
|
Page Count:
|
1
|
|
Description:
|
Commercial Interference; Weight Gain; Email from Russell Giddons, Head of Global Regulatory Affairs for Seroquel, questioning why “limited” would remain as a qualifier to weight gain in the Core Data Sheet even though SERM had decided otherwise.
|
|
Company:
|
AstraZeneca
|
| View as: |
PDF |
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ajv09b10
|
|
